HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – HC Wainwright raised their Q3 2026 earnings estimates for Solid Biosciences in a research note issued on Monday, August 10th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their prior forecast of ($0.41). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.63) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.40) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.23) EPS, FY2029 earnings at $0.27 EPS and FY2030 earnings at $1.80 EPS.

Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Thursday, August 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08.

Several other equities research analysts have also commented on SLDB. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Friday, July 17th. Truist Financial upgraded shares of Solid Biosciences to a “strong-buy” rating in a research note on Monday, April 27th. Wedbush lowered their target price on shares of Solid Biosciences from $17.00 to $16.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $18.00 target price (up from $17.00) on shares of Solid Biosciences in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Solid Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 4th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Solid Biosciences presently has an average rating of “Moderate Buy” and an average price target of $17.11.

Solid Biosciences Price Performance

Shares of SLDB stock opened at $8.85 on Wednesday. The business’s fifty day moving average price is $8.63 and its 200 day moving average price is $7.60. The firm has a market capitalization of $948.90 million, a PE ratio of -4.63 and a beta of 2.41. Solid Biosciences has a 1-year low of $3.79 and a 1-year high of $11.45.

Hedge Funds Weigh In On Solid Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new stake in shares of Solid Biosciences in the second quarter valued at about $2,429,000. Perceptive Advisors LLC increased its stake in shares of Solid Biosciences by 0.6% during the 1st quarter. Perceptive Advisors LLC now owns 11,906,646 shares of the company’s stock worth $85,728,000 after purchasing an additional 73,107 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Solid Biosciences by 12.3% during the 1st quarter. Bank of America Corp DE now owns 386,793 shares of the company’s stock worth $2,785,000 after purchasing an additional 42,499 shares in the last quarter. Stempoint Capital LP acquired a new position in shares of Solid Biosciences during the 1st quarter worth approximately $1,407,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Solid Biosciences during the 1st quarter worth approximately $28,877,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

More Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Solid Biosciences’ third and fourth quarters of 2026, reducing projected losses to approximately $0.38 per share in each quarter. The firm also increased its FY2026 forecast to a loss of $1.63 per share from $1.72.
• Positive Sentiment: The analyst improved estimates across 2027 and 2028, including FY2027 EPS to a loss of $1.59 from $1.72 and FY2028 EPS to a loss of $1.23 from $1.33. These revisions suggest expectations for a faster improvement in profitability.
• Positive Sentiment: HC Wainwright also raised its FY2029 EPS estimate to $0.27 from $0.26, continuing to forecast a transition to positive earnings. The current full-year consensus remains a loss of $1.76 per share, making the revised estimates comparatively favorable.
• Neutral Sentiment: The company’s projected earnings remain negative through FY2028, so the investment case continues to depend on execution and the anticipated longer-term earnings ramp. HC Wainwright forecasts positive EPS of $0.27 in FY2029 and $1.80 in FY2030.
• Negative Sentiment: HC Wainwright trimmed its FY2030 EPS forecast to $1.80 from $1.88. Although the estimate remains strongly profitable, the reduction slightly offsets the otherwise favorable revisions.
• Neutral Sentiment: A report showing August short interest of zero shares does not provide a meaningful short-squeeze or bearish-positioning signal; the data also showed no days to cover.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.